USPTO serial 79448086
REZONBIO
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- BECHHOFER, YOCHEVED D
- Law office
- TMO LAW OFFICE 137
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with REZONBIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 040 | Chemical processing of liquids on a contract or consignment basis and production of biopharmaceutical materials for others; processing of biopharmaceutical materials; production of cell lines for use in biopharmaceutical manufacturing; custom manufacture of biopharmaceuticals; custom manufacture of pharmaceuticals; processing of chemicals; processing of biopharmaceutical materials for others; processing of medical materials; processing of pharmaceutical products; processing of products or materials, in particular the custom manufacture, development, and/or processing of pharmaceutical products for therapeutic purposes, on behalf of and for third parties; preparation of medical products; services for the custom manufacture of pharmaceutical products, veterinary products, cosmetic products, hygiene products, dietary supplements for humans and animals, dietary substances for medical purposes, dietary substances for veterinary purposes, substances, preparations, and chemicals for pharmaceutical purposes, substances, preparations, and chemicals for veterinary purposes, on behalf of other persons; production of a cell line for use in the manufacture of biopharmaceuticals; custom manufacturing and packaging on behalf of third parties of biotechnological drugs (biopharmaceuticals), biosimilars, and other pharmaceutical products; external processing services for pharmaceutical, veterinary, and hygiene products. | ACTIVE | — |
| 042 | Chemical analysis; biochemistry research services; biological research; biotechnological research relating to enzymatic synthesis; chemical research; research relating to biotechnology; research on the subject of pharmaceuticals; genetic research; bacteriological research and analysis; biochemical research and development; pharmaceutical and biological research and development in the field of cell line development, gene expression, gene targeting, protein production, and antibody production; research and development in the field of biotechnology; research and development in the field of biological production and biological development; clinical research; microbiology research; research on unpurified drugs in their natural form; research on the subject of pharmaceuticals; scientific and industrial research and development, biological research, namely the production of proteins and vaccines using biological cells, including the design of cell lines; scientific and industrial research, particularly in the fields of medicine, pharmacy, molecular biology, biotechnology, and genetics; scientific research and genome synthesis services for others; scientific research in the field of genetic engineering; scientific research in the field of genetics and genetic engineering; scientific research; technical research related to mass spectrometry; stem cell research; research and development of medical, diagnostic, and analytical agents, therapeutic methods, and expression systems; consultancy relating to biotechnology; installation of computer software; maintenance of computer software; inspection of pharmaceuticals; medical laboratory services; medical research; scientific and technological services and research and design relating thereto; pharmaceutical product evaluation; development of new pharmaceutical products for therapeutic use on behalf of third parties; development of new hygiene products for third parties; development of new veterinary products for animal therapy on behalf of third parties; development of pharmaceutical preparations and medicines; updating of computer software; writing of computer programs for biotechnological applications; research and development in the pharmaceutical and biotechnology fields; designing and developing software in the field of mobile applications in the areas of medicine, health, and wellness; design and development, on request, of chemical reagents and cell lines; industrial analysis and research services; clinical research; biotechnology testing; developing new technologies for third parties in the following areas: drug discovery and validation, gene expression and delivery, genomic research; development of cell therapy products; preparation of reports in the biotechnology field; material testing; testing of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical research services; research and development services in the field of pharmaceutical products, cosmetic products, veterinary products, hygiene products, dietary supplements for humans and animals, dietary substances for medical purposes, dietary substances for veterinary purposes, substances, preparations, and chemicals for pharmaceutical purposes, substances, preparations, and chemicals for veterinary purposes; research and development services in the field of bacteriology, cell engineering, cytology, antibodies, glycomics, chemistry, microorganisms, proteins, immunology, biological therapeutics, nutraceuticals, and gene expression systems; research services in the fields of medicine, pharmacy, cosmetics, veterinary medicine, and biology; pharmaceutical research and development; research and development services; biochemistry services; chemistry services; medical laboratory services, especially the multiplication or modification of biological cells; medical research laboratory services; laboratory services related to the use of bacterial enzymes for synthesis; pharmaceutical drug development services; services for the development of pharmaceutical, veterinary, and hygiene products; software as a service (saas) covering software for modeling, optimizing assembly, labeling, packaging, and distribution of pharmaceutical products and clinical supplies, as well as their management; design services relating to plant for the biotechnology industry; design services relating to process systems for the biotechnology industry; biochemistry research services; biological research; biomedical research services; laboratory research services relating to pharmaceuticals; services for assessing the efficiency of pharmaceuticals. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 16, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 2, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 2, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 11, 2026 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| May 12, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 11, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 23, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 22, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 22, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 16, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |